Surveillance cultures growing carbapenem-resistant acinetobacter baumannii predict the development of clinical infections: A retrospective cohort study

Clinical Infectious Diseases

Volumn 60, Issue 3, 2015, Pages 415-422

  Latibeaudiere, Rachel ^a   Rosa, Rossana ^a   Laowansiri, Panthipa ^a   Arheart, Kristopher ^a   Namias, Nicholas ^a   Munoz Price, L Silvia ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acinetobacter baumannii; carbapenem resistant; clinical infections; intensive care unit; surveillance cultures

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BIOSURVEILLANCE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG EXPOSURE; FEMALE; HUMAN; IATROGENIC DISEASE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIMARY INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY INFECTION; SEX DIFFERENCE; SKIN INFECTION; SOFT TISSUE INFECTION; SURVEILLANCE CULTURE; SURVIVAL; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTIONS; DRUG EFFECTS; INTENSIVE CARE UNIT; MICROBIOLOGY; MIDDLE AGED; TERTIARY CARE CENTER;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84922463853     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu847     Document Type: Article

References (33)

1. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 1271-81
2. Reddy T, Chopra T, Marchaim D, et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010; 54: 2235-8
3. Spellberg B, Bonomo RA. The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 2014; 42: 1289-91
4. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-Associated infections. N Engl J Med 2014; 370: 1198-208
5. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed 1 February 2014
6. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24: 284-95
7. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46: 1254-63
8. Thom KA, Johnson JK, Lee MS, Harris AD. Environmental contamination because of multidrug-resistant Acinetobacter baumannii surrounding colonized or infected patients. Am J Infect Control 2011; 39: 711-5
9. Rosa R, Depascale D, Cleary T, Fajardo-Aquino Y, Kett DH, Munoz-Price LS. Differential environmental contamination with Acinetobacter baumannii based on the anatomic source of colonization. Am J Infect Control 2014; 42: 755-7
10. Morgan DJ, Liang SY, Smith CL, et al. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol 2010; 31: 716-21
11. Rosa R, Arheart KL, Depascale D, et al. Environmental exposure to carbapenem-resistant Acinetobacter baumannii as a risk factor for patient acquisition of A. baumannii. Infect Control Hosp Epidemiol 2014; 35: 430-3
12. Munoz-Price LS, Carling P, Cleary T, et al. Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: electronic dissemination of a bundle of interventions. Am J Infect Control 2014; 42: 466-71
13. Munoz-Price LS, Arheart K, Nordmann P, et al. Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit Care Med 2013; 41: 2733-42
14. Munoz-Price LS, Namias N, Cleary T, et al. Acinetobacter baumannii: association between environmental contamination of patient rooms and occupant status. Infect Control Hosp Epidemiol 2013; 34: 517-20
15. Garner JS, JarvisWR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40
16. Welch K. Checking for multicollinearity using SAS. Available at: http://www-personal.umich.edu/~kwelch/finan/day3-finan-collin.doc. Accessed 24 May 2014
17. Allison PD. Survival analysis using SAS. Cary, NC: SAS Press, 2010
18. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65: 204-11
19. Shih MJ, Lee NY, Lee HC, et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect 2008; 41: 118-23
20. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-Associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-55
21. Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008; 12: 16-21
22. Jung JY, Park MS, Kim SE, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 2010; 10: 228
23. Wisplinghoff H, PerbixW, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999; 28: 59-66
24. Beck-Sague CM, Jarvis WR, Brook JH, et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol 1990; 132: 723-33
25. Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998; 129: 182-9
26. Zheng YL, Wan YF, Zhou LY, et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am J Infect Control 2013; 41: e59-63
27. Chiang MC, Kuo SC, Chen SJ, et al. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40: 19-26
28. Chopra T, Marchaim D, Awali RA, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 2013; 57: 6270-5
29. Linde-Zwirble W. When is simple too simple? Immortal time bias in critical care. Crit Care Med 2009; 37: 2990-1
30. Coyle JR, Kaye KS, Taylor T, et al. Effectiveness and cost of implementing an active surveillance screening policy for Acinetobacter baumannii: a Monte Carlo simulation model. Am J Infect Control 2014; 42: 283-7
31. Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: thinking" out of the box." Vaccine 2014; 32: 2537-9
32. Landelle C, Marimuthu K, Harbarth S. Infection control measures to decrease the burden of antimicrobial resistance in the critical care setting. Curr Opin Crit Care 2014; 20: 499-506
33. Tosh PK, McDonald LC. Infection control in the multidrugresistant era: tending the human microbiome. Clin Infect Dis 2012; 54: 707-13